Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights
May 08, 2024 06:45 ET
|
Compass Pathways
COMP360 phase 3 pivotal program in treatment-resistant depression (TRD) on track for top-line COMP005 trial data in fourth quarter 2024, COMP006 trial top-line data expected mid-2025Compass announces...
Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder
May 08, 2024 06:30 ET
|
Compass Pathways
Study met primary safety endpoint; administration was well tolerated, with no serious adverse events observed Early and clinically meaningful improvement from baseline in mean CAPS-5 total score (29.5...
Compass Pathways to announce first quarter financial results on May 8, 2024
May 03, 2024 16:58 ET
|
Compass Pathways
LONDON, May 03, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health,...
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
May 02, 2024 06:30 ET
|
Compass Pathways; Mindful Health Solutions
LONDON, May 02, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...
Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression
April 29, 2024 06:30 ET
|
Compass Pathways
LONDON, April 29, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...
Compass Pathways to participate in upcoming 23rd Annual Needham Virtual Healthcare Conference
April 01, 2024 16:01 ET
|
Compass Pathways
LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health,...
Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors
March 28, 2024 08:00 ET
|
Compass Pathways
LONDON, March 28, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...
Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights
February 29, 2024 07:00 ET
|
Compass Pathways
LONDON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Highlights: COMP360 phase 3 pivotal program ongoing; COMP005 trial top-line data now expected in fourth quarter 2024, COMP006 remains on track for top-line...
Compass Pathways to participate in upcoming TD Cowen investor conference
February 26, 2024 16:01 ET
|
Compass Pathways
LONDON, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health,...
Compass Pathways to announce fourth quarter and year-end 2023 financial results on February 29, 2024
February 22, 2024 16:01 ET
|
Compass Pathways
LONDON, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health,...